Telix Pharmaceuticals lifts revenue guidance after strong third quarter performance

Telix Pharmaceuticals (ASX:TLX) has raised its full-year revenue guidance to between US$800 million and US$820 million following a solid third quarter marked by 53 per cent year-on-year revenue growth, reimbursement wins for Gozellix in the United States, and further expansion of its commercial footprint in Europe. …